Design of Therapeutic Peptide-Based Nanoparticles
Design of Therapeutic Peptide-Based Nanoparticles
批准号:
8607902
负责人:
VADIM V GAPONENKO
金额:
$30.65万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-02-04 至 2016-01-31
关键词:
AddressAmino Acid SubstitutionAntineoplastic AgentsBindingBiodistributionBiologicalBiological AssayBloodCCR5 geneCXCR4 geneCell membraneCircular DichroismClinicalComplexConeDevelopmentDimethyl SulfoxideDiseaseDrug IndustryElectron MicroscopyEnvironmentExhibitsGoalsGrowthGuidelinesHIVHIV Entry InhibitorsHydrophobic InteractionsInvestmentsJointsKnowledgeLearningLifeLipidsLiposomesLysosomesMalignant NeoplasmsMarketingMedicineMembraneMembrane ProteinsMicellesModelingMolecular ConformationMulti-Drug ResistanceMusMutationNanostructuresNuclear Magnetic ResonanceP-GlycoproteinPeptide ConformationPeptidesPermeabilityPharmaceutical PreparationsPharmacologic SubstanceProblem SolvingPropertyProteinsReceptor InhibitionReportingResearchResistance developmentSecretinSerumSolutionsSolventsSpecificityStreamStructureTechniquesTestingTherapeuticTherapeutic AgentsTreatment Efficacyamphiphilicityaqueousbasecancer cellchemokine receptorcommon ruledesigninhibitor/antagonistintermolecular interactionlight scatteringmalignant breast neoplasmmutantnanoparticlenovelnovel strategiesnovel therapeuticsparticlepeptide analogpeptide hormonepeptide structurepreventpublic health relevanceself assemblysmall moleculetargeted deliverytumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): With increasing investment into pharmaceutical industry there is a paradoxical decline in the number of new medicines on the market. One of the reasons for this phenomenon is the focus of pharmaceutical companies on small molecules for development of therapeutic agents. Although they are potent inhibitors of target proteins, small molecules are known for their low specificity. Larger and more complex molecules, such as peptides, provide more specific target recognition. However, peptides are unstable and require design of cellular delivery mechanisms. Utilization of structural plasticity of peptide molecules in biological solvents is a novel approach to solve the problems with peptide pharmaceutical agents. In aqueous solutions certain peptides exhibit a distinct beta-hairpin conformation that allows them to assemble into spherical nanostructures. Nanostructures encounter a hydrophobic environment of the plasma membrane, disassemble, insert into the membrane, change their conformation, and inhibit target proteins. I hypothesize that by studying the peptide assembly mechanism into nanoparticles it is possible to formulate a set of requirements for the design of peptides capable to form nanoparticles. The long term goal is to define the requirements for intermolecular interactions between peptides allowing assembly into nanoparticles. Understanding the mechanism of peptide structure transitions will enable development of novel therapeutic nanoparticles capable of performing an encoded sequence of tasks. I shall address the requirements for the design of such peptides by studying the structure of the monomeric peptides, the mechanism of nanoparticle assembly, and the structural changes in the lipid environment. I propose the following specific aims: (1) Determine the structural requirements for the monomeric peptide that allow assembly into nanoparticles using nuclear magnetic resonance (NMR) techniques; (2) Identify the intermolecular interactions responsible for peptide assembly into nanoparticles using NMR, electron microscopy, and dynamic light-scattering; (3) Analyze structural changes that the peptide molecules undergo in the lipid environment by NMR.
期刊论文(12)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1088/0957-4484/22/50/505101
发表时间:
2011-12-16
期刊:
Nanotechnology
影响因子:
3.5
作者:
[Lee Y, Chen Y, Tarasova NI, Gaponenko V]
通讯作者:
Gaponenko V
DOI:
10.1002/cbic.201000563
发表时间:
2011-04-11
期刊:
CHEMBIOCHEM
影响因子:
3.2
作者:
[Johannessen, Liv, Remsberg, Jarrett, Gaponenko, Vadim, Adams, Kristie M., Barchi, Joseph J., Jr., Tarasov, Sergey G., Jiang, Sheng, Tarasova, Nadya I.]
通讯作者:
Tarasova, Nadya I.
DOI:
10.1016/j.trecan.2017.01.007
发表时间:
2017-03
期刊:
Trends in cancer
影响因子:
18.4
作者:
[Nussinov R, Wang G, Tsai CJ, Jang H, Lu S, Banerjee A, Zhang J, Gaponenko V]
通讯作者:
Gaponenko V
Partial agonist activity of α1-adrenergic receptor antagonists for chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3.
α1-肾上腺素能受体拮抗剂对趋化因子(C-X-C 矩阵)受体 4 和非典型趋化因子受体 3 的部分激动活性。
DOI:
10.1371/journal.pone.0204041
发表时间:
2018
期刊:
PloS one
影响因子:
3.7
作者:
[Gao X, Abdelkarim H, Albee LJ, Volkman BF, Gaponenko V, Majetschak M]
通讯作者:
Majetschak M
Application of reductive ¹³C-methylation of lysines to enhance the sensitivity of conventional NMR methods.
赖氨酸的还原性αC-甲基化的应用以增强常规NMR方法的敏感性。
DOI:
10.3390/molecules18067103
发表时间:
2013-06-18
期刊:
Molecules (Basel, Switzerland)
影响因子:
--
作者:
[Chavan TS, Abraham S, Gaponenko V]
通讯作者:
Gaponenko V
共 6 条
Regulation of tyrosine kinase signaling through interaction with membrane lipids
-
批准号:8887665
-
项目类别:
-
资助金额:$43.0万
-
财政年份:2015
-
负责人:VADIM V GAPONENKO
-
依托单位:
Peptide-based nanoparticle inhibition of CCR3-mediated inflammatory cell recruitm
-
批准号:8488242
-
项目类别:
-
资助金额:$22.78万
-
财政年份:2013
-
负责人:VADIM V GAPONENKO
-
依托单位:
Peptide-based nanoparticle inhibition of CCR3-mediated inflammatory cell recruitm
-
批准号:8663608
-
项目类别:
-
资助金额:$19.54万
-
财政年份:2013
-
负责人:VADIM V GAPONENKO
-
依托单位:
Design of Therapeutic Peptide-Based Nanoparticles
-
批准号:8212263
-
项目类别:
-
资助金额:$31.6万
-
财政年份:2010
-
负责人:VADIM V GAPONENKO
-
依托单位:
Design of Therapeutic Peptide-Based Nanoparticles
-
批准号:7783460
-
项目类别:
-
资助金额:$31.39万
-
财政年份:2010
-
负责人:VADIM V GAPONENKO
-
依托单位:
Design of Therapeutic Peptide-Based Nanoparticles
-
批准号:8020925
-
项目类别:
-
资助金额:$31.6万
-
财政年份:2010
-
负责人:VADIM V GAPONENKO
-
依托单位:
Design of Therapeutic Peptide-Based Nanoparticles
-
批准号:8433502
-
项目类别:
-
资助金额:$29.7万
-
财政年份:2010
-
负责人:VADIM V GAPONENKO
-
依托单位:
海外基金